Nailing down what Oppenheimer analyst Jay Olson characterized as “a trifecta,” Immuneering Corp. unveiled positive updated survival and safety data from the ongoing phase IIa trial testing oral, once-daily MEK inhibitor atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxe in first-line pancreatic cancer patients.